WEST PHARMACEUTICAL SERVICES INC (WST) — Congressional Stock Trades & Intelligence
WEST PHARMACEUTICAL SERVICES INC (WST) is an active recipient of U.S. federal and defense procurement awards. According to federal procurement records and obligation filings, the company has been awarded 0 prime federal contracts and delivery orders totaling approximately $0 across 1 federal awarding agencies, with the most recent award action registered on —.
Federal contracts represent substantial multi-year revenue visibility for prime contractors and defense suppliers. Gemral Edge continuously reconciles federal award obligations from the Federal Procurement Data System (FPDS) and USAspending with congressional disclosures, tracking capital flow from policy authorization through corporate execution.
Verified from official public disclosure — record WST-CONGRESS-DISCLOSURE
Quick Facts & Defense Contracting Direct Answers
How much does WEST PHARMACEUTICAL SERVICES INC receive in federal government contracts?
WEST PHARMACEUTICAL SERVICES INC has been awarded over $0 in tracked prime federal obligations across 1 awarding agencies, as recorded in official FPDS and USAspending data.
Which congressional lawmakers trade WEST PHARMACEUTICAL SERVICES INC (WST) stock?
Public Periodic Transaction Reports (PTR) under the STOCK Act record transactions in WEST PHARMACEUTICAL SERVICES INC (WST) by members of Congress including Jared Moskowitz, Lisa C Mcclain, Tommy Tuberville.
How are federal defense contracts mapped to WEST PHARMACEUTICAL SERVICES INC on Gemral Edge?
Gemral Edge programmatically reconciles prime award obligations from SAM.gov, USAspending, and FPDS through corporate parent CAGE and UEI hierarchies directly to ticker WST.
Unified Ticker Intelligence Dossier (WST)
Synthesis: Mã WST ghi nhận dữ liệu hoạt động tổng hợp qua các kênh công quyền và dòng tiền.
Temporal Context: Dữ liệu các kênh hoạt động đang trong trạng thái theo dõi chu kỳ đối với WST.
Data Coverage & Verification: Overall coverage score: 33% across 6 pillars (Government, Policy, Flow, Management, Catalysts, Historical). Verified by 2 independent statutory data sources.
Congressional Stock Trading Activity in WST
Disclosed stock purchases and sales by members of Congress and spouses involving WEST PHARMACEUTICAL SERVICES INC securities under the STOCK Act:
| Lawmaker | Party-State | Chamber | Transaction Date | Action | Disclosed Range | Est. Return |
|---|---|---|---|---|---|---|
| Lisa C. McClain | R-MI | HOUSE | 2025-06-17 | BUY | $1K – $15K | +58.8% |
| Jared Moskowitz | D-FL | HOUSE | 2025-02-13 | SELL | $1K – $15K | +73.9% |
| Jared Moskowitz | D-FL | HOUSE | 2023-12-28 | BUY | $1K – $15K | -2.5% |
| Tommy Tuberville | R-AL | SENATE | 2022-03-30 | SELL | $1K – $15K | -17.2% |
| Donna E. Shalala | D-FL | HOUSE | 2019-06-24 | SELL | $1K – $15K | +183.3% |
| Greg Gianforte | R-MT | HOUSE | 2018-09-25 | BUY | $50K – $100K | +182.4% |
| Josh Gottheimer | D-NJ | HOUSE | 2018-01-24 | SELL | $1K – $15K | +245.2% |
| Lamar Smith | R-TX | HOUSE | 2018-04-30 | BUY | $1K – $15K | +292.5% |
| Lamar Smith | R-TX | HOUSE | 2018-01-18 | BUY | $1K – $15K | +251.2% |
Related Congressional Committees & Active Lawmakers
Disclosed lawmakers and congressional committees holding policy jurisdiction, defense appropriations oversight, or direct capital exposure in WST:
- Lisa C. McClain (House) — Disclosed STOCK Act transactions (R-MI)
- Jared Moskowitz (House) — Disclosed STOCK Act transactions (D-FL)
- Tommy Tuberville (Senate) — Disclosed STOCK Act transactions (R-AL)
- Donna E. Shalala (House) — Disclosed STOCK Act transactions (D-FL)
- Greg Gianforte (House) — Disclosed STOCK Act transactions (R-MT)
- Josh Gottheimer (House) — Disclosed STOCK Act transactions (D-NJ)
- Lamar Smith (House) — Disclosed STOCK Act transactions (R-TX)
- Nancy Pelosi (House) — Former Speaker of the House (D-CA)
Latest Real-Time Intelligence & Breaking Events
Live contract obligations, SEC filings, and procurement intelligence for WEST PHARMACEUTICAL SERVICES INC are monitored 24/7 on Gemral Edge Breaking News and Defense Radar.
Federal Contracting Dynamics & Government Revenue Exposure
Government contracting for defense and enterprise infrastructure follows strict Federal Acquisition Regulation (FAR) guidelines, often spanning multi-year base periods with optional extension years. Monitoring prime contractor award velocity provides institutional investors and market participants with un-lagged visibility into backlog expansion, agency budget priorities, and defense authorization funding flows.
Furthermore, when members of congressional defense, intelligence, or appropriations committees disclose trading activity in major federal contractors such as WEST PHARMACEUTICAL SERVICES INC, cross-referencing contract award timelines with legislative disclosures highlights important intersections of public policy and corporate performance.
Frequently asked questions
How much does WEST PHARMACEUTICAL SERVICES INC receive in federal government contracts?
WEST PHARMACEUTICAL SERVICES INC holds over $0 in tracked federal obligations across 1 public agencies, providing multi-year revenue visibility across defense and civilian procurement budgets.
Which congressional lawmakers trade WEST PHARMACEUTICAL SERVICES INC (WST) stock?
WEST PHARMACEUTICAL SERVICES INC (WST) stock transactions have been disclosed by members of Congress including Jared Moskowitz, Lisa C Mcclain, Tommy Tuberville. Disclosures filed under the STOCK Act detail execution dates, asset classes, and statutory valuation ranges.
How are federal defense contracts resolved to WEST PHARMACEUTICAL SERVICES INC?
Gemral Edge maps prime award notices from the Federal Procurement Data System (FPDS) and USAspending through Ultimate Parent CAGE and UEI corporate hierarchies directly to parent ticker WST.
What technology stack signals are detected for WEST PHARMACEUTICAL SERVICES INC?
Active talent hiring requisitions and engineering role profiles are continuously monitored across public corporate job postings to track enterprise software adoption and technology migration patterns.
Data intelligence from public filings — not investment advice.